Immunomedics
Immunomedics
Former pharmaceutical company
Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.[1]
Quick Facts Industry, Founded ...
| Industry | Biotechnology |
|---|---|
| Founded | July 1982; 41 years ago (1982-07) |
| Founder | David M. Goldenberg |
| Defunct | October 23, 2020; 3 years ago (2020-10-23) |
| Headquarters | Morris Plains, New Jersey |
| Parent | Gilead Sciences |
| Website | www |
Close
Immunomedics was founded in July 1982 by David M. Goldenberg.[2]
Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]
In October 2020, Gilead Sciences acquired the company.[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains. [5]
- Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.[citation needed]
- Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.[6] In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg.[7]
- Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.[citation needed]
- Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.[citation needed]
- Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.[citation needed]
- IMMU-114 is an anti-HLA-DR for hematological cancers.[8]
- "Gilead Sciences Completes Acquisition of Immunomedics, Inc" (Press release). Business Wire. October 23, 2020.
- Vinluan, Frank (February 28, 2019). "Immunomedics CEO Michael Pehl Resigns". Xconomy.
- "Immunomedics Form 8-K". U.S. Securities and Exchange Commission. February 22, 2019.
- LEE, ARMIE MARGARET (May 5, 2017). "Immunomedics, Seattle Genetics Scrap License Deal". TheStreet.com.
- Chen, X; Chang, C-H; Stein, R; Goldenberg, D M (October 24, 2011). "The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD". Nature. 47 (7): 967–980. doi:10.1038/bmt.2011.203. PMID 22020022. S2CID 8988947.